Skip to main content
Boule Diagnostics logo

Boule Diagnostics — Investor Relations & Filings

Ticker · BOUL ISIN · SE0011231158 LEI · 213800IK1TGY858TKZ45 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2020-04-02 Notice of Dividend Amou…
Country SE Sweden
Listing ST BOUL

About Boule Diagnostics

https://boule.com/

Boule Diagnostics is a global provider of diagnostic solutions specializing in hematology. The company develops, manufactures, and markets systems and consumables for blood diagnostics, including hematology analyzers, clinical chemistry analyzers, and associated reagents, controls, and calibrators. Its products are tailored for decentralized healthcare settings in both the human and veterinary markets, such as smaller laboratories and clinics. The company aims to enhance global healthcare access by providing high-quality instruments that deliver timely and accurate blood test results.

Recent filings

Filing Released Lang Actions
Boule Diagnostics förslag till utdelning dras tillbaka
Notice of Dividend Amount Classification · 1% confidence The document is a short announcement in Swedish titled "Boule Diagnostics förslag till utdelning dras tillbaka" (Boule Diagnostics proposed dividend is withdrawn). It explicitly states that the Board of Directors has decided to withdraw the previously communicated proposal for a dividend of 0.60 SEK per share and instead proposes no dividend payment, citing increased market uncertainty due to the Coronavirus. This is a direct announcement regarding a change in dividend policy/proposal, which aligns perfectly with the definition for 'Notice of Dividend Amount' (DIV), even though it is a withdrawal rather than a declaration of a new amount. Given the content focuses solely on the dividend decision and is very brief (2126 chars), DIV is the most appropriate classification.
2020-04-02 Swedish
Boule Diagnostics erhåller stängning av varningsbrev från amerikanska myndigheten FDA
Legal Proceedings Report Classification · 1% confidence The document is a short announcement dated February 29, 2020, detailing that Boule Diagnostics received confirmation from the US FDA that the warning letter issued on October 2, 2018, has been closed following the company's corrective actions. This concerns regulatory compliance and legal/regulatory matters. It is not a full report (like 10-K or IR), nor is it a standard earnings release (ER) or dividend notice (DIV). It specifically addresses the resolution of a regulatory action/warning letter. This fits best under Legal Proceedings Report (LTR) as it concerns significant regulatory action resolution, or potentially Regulatory Filings (RNS) as a general regulatory update. Given the specific nature of resolving a formal FDA warning letter, LTR is the most precise fit among the specific categories, as it relates to legal/regulatory proceedings outcome. The final paragraph confirms it is an official disclosure under EU market abuse regulation.
2020-02-29 Swedish
Earnings Release 2019
Earnings Release Classification · 1% confidence The document is titled "Bokslutskommuniké januari–december 2019" (Year-end report January–December 2019) and provides detailed financial results for the fourth quarter (oktober-december 2019) and the full fiscal year (januari-december 2019). It includes key performance indicators (Net sales, Operating result, Earnings per share), management commentary ("VD har ordet"), and detailed financial breakdowns (Revenue, Gross Profit, Costs, Cash Flow, Investments, Equity). This structure is characteristic of a comprehensive annual financial report, which aligns with the definition of an Annual Report (10-K), although the specific filing code 10-K is typically for US SEC filings. Given the context of a comprehensive yearly financial report, the closest equivalent in the provided definitions is the Annual Report (10-K). Since the document is a full report and not just an announcement of a report, it is not RPA or RNS. It is too detailed to be just an Earnings Release (ER) or Interim Report (IR). FY 2019
2020-02-07 Swedish
Christina Rubenhag utses till tillförordnad VD och Peter Ehrenheim till arbetande styrelseordförande i Boule Diagnostics
Board/Management Information Classification · 1% confidence The document announces significant changes in senior management: the appointment of Christina Rubenhag as interim CEO and Peter Ehrenheim as executive chairman, effective upon the departure of the current CEO. This content directly relates to changes in the company's board of directors or senior management personnel. This aligns perfectly with the definition for Board/Management Information (MANG). The document is short and contains the announcement itself, not a link to a larger report.
2019-12-13 Swedish
Jesper Söderqvist utses till ny VD i Boule Diagnostics
Board/Management Information Classification · 1% confidence The document text is a press release announcing the appointment of Jesper Söderqvist as the new CEO of Boule Diagnostics AB, effective May 11, 2020. This announcement details changes in senior management personnel. According to the definitions, announcements of changes in the company's board of directors or senior management fall under the 'Board/Management Information' category, which corresponds to the code MANG. The document is short and appears to be a direct announcement, not a comprehensive report.
2019-11-11 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for Boule Diagnostics AB for the period January–September 2019. It contains comprehensive financial statements, including income statements, cash flow analysis, regional/product sales breakdowns, and management commentary on business performance. It is not an announcement of a report (RPA) as it contains the full substantive financial data and analysis for the specified period. 9M 2019
2019-10-30 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.